BEDFORD, Mass., March 6, 2014 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products with an emphasis on serving the healthcare needs of women, announced today that the American Medical Association (AMA) CPT Editorial Panel posted its Summary of Panel Actions from the February, 2014 Panel Meeting.
According to the Summary of Panel Actions, the application submitted for breast tomosynthesis was accepted for three Category I CPT codes that include screening and diagnostic breast tomosynthesis.
The Summary of Panel Actions is a preliminary step and codes are not assigned, nor is exact wording finalized, until just prior to the publication of the CPT Professional Edition 2015. The Medicare payment rates associated with the breast tomosynthesis codes will not be posted until the Medicare Physician Fee Schedule Final Rule is issued by the Centers for Medicare & Medicaid Services (CMS) on or around November 1, 2014. The CPT codes and rates are scheduled for implementation January 1, 2015. For additional information, please refer to the Summary of Panel Actions available on the AMA website.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
CPT is a registered trademark of the American Medical Association.
SOURCE Hologic, Inc.